Story perspectives

U.S. Strikes $149 Deal for Weight-Loss Drugs

11/5/2025

Summary

Story summary

The U.S. administration is nearing a deal with Eli Lilly and Novo Nordisk to set the price of their weight-loss drugs at $149 per month in exchange for Medicare coverage.
The drugs currently cost more than $1,000 per month.
If finalized, the arrangement would mark a major step in U.S. President Donald Trump's effort to lower prescription drug costs and expand Medicare access, following similar agreements with other pharmaceutical companies.

History

Historical Context

The Medicare Prescription Drug, Improvement, and Modernization Act, enacted in 2003, introduced Medicare Part D, providing voluntary prescription drug coverage for seniors. This legislation marked a significant shift in Medicare, allowing private insurers to manage benefits. As drug prices have surged, recent negotiations with companies like Eli Lilly and Novo Nordisk aim to enhance Medicare's role in regulating costs and improving access for vulnerable populations.

1 of 2

Story summary

The U.S. administration is nearing a deal with Eli Lilly and Novo Nordisk to set the price of their weight-loss drugs at $149 per month in exchange for Medicare coverage.
The drugs currently cost more than $1,000 per month.
If finalized, the arrangement would mark a major step in U.S. President Donald Trump's effort to lower prescription drug costs and expand Medicare access, following similar agreements with other pharmaceutical companies.

1 / 2